EGFR and neoplasm: As previously observed in vitro, pladienolide B administration in vivo significantly decreased various relevant tumor progression markers and critical oncogenic spliceosome components (VEGFA/EGFR/CDK4/PDGFRA/PDGFRB and SRSF3/PTBP1; Fig. 6h-i).